Related Experiment Videos
[Platelet function and high-dose methotrexate treatment with citrovorum factor rescue]
Onkologie
|August 1, 1984
Summary
High-dose methotrexate (HDMTX) and cisplatin (CFR) therapy can cause bleeding. While not always explained by low platelets, this study found HDMTX/CFR can impair platelet function, warranting further investigation in patients with bleeding issues.
Area of Science:
- Hematology
- Pharmacology
- Pediatric Oncology
Context:
- High-dose methotrexate (HDMTX) and cisplatin (CFR) are critical in treating various cancers.
- Bleeding complications are observed with HDMTX/CFR therapy, but the underlying mechanisms remain incompletely understood.
- Platelet function has not been previously evaluated in the context of HDMTX/CFR treatment.
Purpose:
- To investigate the impact of HDMTX and CFR on platelet function.
- To determine if MTX directly affects platelet aggregation and function in vitro.
- To assess ex vivo platelet function in children receiving HDMTX/CFR therapy.
Summary:
- In vitro studies demonstrated that methotrexate (MTX) inhibits platelet aggregation and reduces platelet factor 3 availability in a dose-dependent manner.
- Ex vivo analysis of 10 children treated with HDMTX/CFR revealed impaired platelet factor 3 release, although platelet aggregation remained normal.
- No severe platelet function disturbances were identified during HDMTX/CFR treatment, suggesting a potential for subtle, individual-specific impairments.
Impact:
- This research highlights the potential for HDMTX/CFR to affect platelet function, even if not always clinically severe.
- It suggests that platelet function testing may be valuable for diagnosing unexplained bleeding in patients undergoing HDMTX/CFR therapy.
- Understanding these effects can lead to improved patient monitoring and management of bleeding complications in pediatric oncology.